echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > 60 years blank! "Hyperkalemia" ushers in the first new drug!

    60 years blank! "Hyperkalemia" ushers in the first new drug!

    • Last Update: 2020-01-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    AstraZeneca official announcement: the new oral potassium reducing drug ribeizhuo (general name: sodium zirconate cyclosilicate powder) has been approved by the State Drug Administration of China for marketing, and is used to treat adult hyperkalemia The drug treatment of hyperkalemia has experienced a blank period of nearly 60 years As the first innovative drug on the market in China, the approval of sodium zirconate cyclosilicate powder marks a new era of hyperkalemia treatment in China In the first half of 2019, because of its unique mechanism of action and clinical efficacy, sodium zirconate cyclosilicate powder can help patients with hyperkalemia to solve the unmet treatment needs It was included in the second batch of "list of clinically urgent overseas new drugs" by the drug review center of the State Drug Administration, and was first reviewed and approved Hyperkalemia (serum potassium level > 5.0mmol/L) is one of the important complications of chronic kidney disease and heart failure The incidence rate gradually increases with the progression of disease, and the recurrence and interval gradually shorten Chronic kidney disease is the sixth leading cause of death in China: the incidence rate is as high as 10.8%, the number of patients is over 100 million, and nearly 40% of them suffer from death due to arrhythmia / cardiac arrest With the approval of sodium zirconate cyclosilicate powder, it brings hope for the huge clinical demand of Chinese hyperkalemia patients Adorable adorable
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.